» Articles » PMID: 16530420

Histopathology of BRCA1- and BRCA2-associated Breast Cancer

Overview
Specialty Hematology
Date 2006 Mar 15
PMID 16530420
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary breast carcinomas that are attributable to BRCA1/2 mutations have their own morphological and immunohistochemical characteristics. BRCA1-associated carcinomas are poorly differentiated infiltrating ductal carcinomas that frequently show morphological features of typical or atypical medullary carcinoma. BRCA2-associated breast carcinomas tend to be of higher grade than sporadic age-matched controls. BRCA1tumors have been found to be more frequently estrogen receptor- and progesterone receptor-negative, and p53-positive than are age-matched controls, whereas these differences are not usually found in BRCA2-associated tumors. In addition, BRCA1- and BRCA2-associated breast carcinomas show a low frequency of HER2 expression. Most BRCA1 breast carcinomas are characterized by the expression of basal (myoepithelial) markers, such as cytokeratin 5/6 and or P-cadherin. These features could be used to distinguish patients who are likely to carry a BRCA1 or BRCA2 germline mutation, thus indicating which gene should be screened for first in families with a high incidence of breast and ovarian cancer.

Citing Articles

Thirty Years of BRCA1: Mechanistic Insights and Their Impact on Mutation Carriers.

Moser S, Jonkers J Cancer Discov. 2025; 15(3):461-480.

PMID: 40025950 PMC: 11893084. DOI: 10.1158/2159-8290.CD-24-1326.


Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers.

Alfaro A, Catelain C, El-Masri H, Rameau P, Lacroix-Triki M, Scoazec J NPJ Breast Cancer. 2024; 10(1):81.

PMID: 39277640 PMC: 11401883. DOI: 10.1038/s41523-024-00691-x.


Pathologic complete response after neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers.

Myers S, Sevilimedu V, Barrio A, Tadros A, Mamtani A, Robson M NPJ Breast Cancer. 2024; 10(1):63.

PMID: 39060255 PMC: 11282097. DOI: 10.1038/s41523-024-00674-y.


BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy.

Toss A, Molinaro E, Venturelli M, Domati F, Marcheselli L, Piana S Cancers (Basel). 2020; 12(5).

PMID: 32429297 PMC: 7281631. DOI: 10.3390/cancers12051252.


Hereditary breast and ovarian cancer in Andalusian families: a genetic population study.

Pajares B, Porta J, Porta J, Sousa C, Moreno I, Porta D BMC Cancer. 2018; 18(1):647.

PMID: 29884136 PMC: 5994127. DOI: 10.1186/s12885-018-4537-9.